Pharmacologic strategies in prediabetic neuropathy

Area of Science:

• Neurology
• Endocrinology
• Metabolic Disorders

Background:

• Prediabetic neuropathy involves early nerve dysfunction before type 2 diabetes diagnosis.
• Significant numbers of individuals with prediabetes exhibit neuropathic changes, particularly affecting small sensory fibers and autonomic nerves.
• Pathophysiology involves interconnected metabolic and vascular factors like oxidative stress, inflammation, and impaired insulin signaling.

Purpose of the Study:

• To review the current understanding of prediabetic neuropathy.
• To discuss the limitations of current management strategies.
• To explore emerging therapeutic approaches for early nerve dysfunction in prediabetes.

Main Methods:

• Literature review of epidemiological and preclinical/clinical studies.
• Analysis of proposed pathophysiological mechanisms.
• Evaluation of current and emerging pharmacological and lifestyle interventions.

Main Results:

• Prediabetic neuropathy is common, impacting small sensory and autonomic nerves.
• Existing treatments primarily aim to prevent type 2 diabetes progression, not directly address nerve damage.
• Novel therapies (e.g., RAS modulation, SGLT2 inhibitors, antioxidants) show promise but require more clinical validation.
• Underdiagnosis and lack of large trials hinder clinical translation.

Conclusions:

• Early, mechanism-based interventions combining pharmacological and lifestyle approaches are suggested.
• Stronger clinical evidence is required to support new treatment strategies for prediabetic neuropathy.
• Addressing early nerve dysfunction in prediabetes is crucial for long-term patient outcomes.